J Clin Rheumatol. 2023;29(5):223–229 doi: 10.1097/RHU.0000000000001973
Phase 2a study assessing the efficacy and safety of tildrakizumab in patients with active AS fails to meet the primary endpoint.
The IL-23 and IL-17A signalling pathway is implicated in AS pathogenesis, and inhibitors of both have been assessed as potential treatments for AS, with secukinumab and ixekizumab (IL-17 inhibitors) approved for the treatment of AS in the USA.
As the IL-23 inhibitor tildrakizumab is already approved for use in moderate-to-severe plaque psoriasis, Peters, et al. sought to establish the efficacy and safety of the therapy in patients with AS.